$OBIO

Sherman Darren purchased $11K of OBIO (indirect holdings)

Sherman Darren (See Remarks) purchased 2,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.33 on 2026-08-26.

Original reporting
SEC EDGAR · Sherman Darren
Published Aug 28, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OBIO
Neutral
low confidence
Mentioned
$OBIO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The filing provides a fresh, primary source of insider activity but the transaction size is too small to drive price action.

02

Market read

Insider purchase is a low‑impact event; traders may note it but unlikely to alter positioning.

03

What to watch

Potential upcoming clinical milestones not disclosed in this filing.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-28

Background

Form 4 filings disclose insider trades; small purchases are common and often have limited market impact.

Company-level read

Ticker impact

$OBIONeutralLow confidence
Context

Officer/director Sherman Darren bought 2,000 shares of Orchestra BioMed Holdings for $10,660 via a Form 4 filing.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The purchase amount is modest for a public company and does not represent a significant capital allocation.

Market effects

None significant for the biotech sector.

No regional effect.

Limited to investors tracking insider activity.

Counterpoint

The purchase could be a routine portfolio adjustment rather than a confidence signal.

Key entities

  • Orchestra BioMed Holdings, Inc.

    Biotech firm focused on oncology therapeutics.

  • Sherman Darren

    Officer and director of OBIO.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $15.0M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 28,696 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $521.34 ($515.53–$529.16, $14.96M total) across 15 trades on 2026-09-04. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).